n
|
234
|
Follow-up period, years, median (range)
|
4.9 (2–11)
|
Age, years, median (range)
|
70 (46–86)
|
MMSE score, mean ± SD
|
24 ± 5
|
Female sex
|
145 (62)
|
Coresidency status
| |
Cohabiting (female/male)
|
99 (68)/79 (89)
|
Living alone (female/male)
|
46 (32)/10 (11)
|
Education (years)
| |
≤7
|
114 (49)
|
8–12
|
71 (30)
|
≥13
|
49 (21)
|
CSF biomarkersa according to baseline AD stage, mean ± SD
|
t-tau, ng/L
|
MCI 723 ± 354, dementia 780 ± 558
|
p-tau, ng/L
|
MCI 102 ± 43, dementia 102 ± 48
|
Aβ42, ng/L
|
MCI 351 ± 114, dementia 374 ± 124
|
All three biomarkers normala
|
5 (2)
|
Low Aβ42, normal t-tau and p-tau
|
21 (9)
|
Low Aβ42, high t-tau or p-tau
|
48 (21)
|
Normal Aβ42, high t-tau and/or p-tau
|
29 (12)
|
All three biomarkers pathological
|
131 (56)
|
Baseline AD stage, n (%); MMSE score, mean (SD)
| |
MCI
|
134 (57); 26 ± 3
|
Mild dementia
|
85 (36); 22 ± 4
|
Moderate dementia
|
15 (7); 15 ± 6
|
NHP during follow-up
|
112 (48)
|
Males/females
|
34 (38)/78 (54)
|
MCI/dementia stage at baseline
|
54 (40)/58 (58)
|
Conversion to moderate dementia, n = 219
|
149 (68)
|
From MCI at baseline
|
83/134 (62)
|
From mild dementia at baseline
|
66/86 (77)
|
Rapid cognitive declineb
|
57 (24)
|
MCI
|
22 (16)
|
Mild to moderate dementia
|
35 (35)
|
Death during follow-up
|
83 (35)
|
Death in severe dementia during follow-up
|
46 (20)
|
MCI
|
19 (14)
|
Mild to moderate dementia
|
27 (27)
|